Brian Jacobs, MD
Ophthalmology · Libertyville, ILNPI 1730146218
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 72.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $7,332 and has fallen 85.3% since, to $1,077 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $49.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Alcon$715
- Oyster Point Pharma, Inc.$450
- Aerie Pharmaceuticals, Inc.$353
- Novartis$293
- Thea Pharma Inc.$203
- plus $1K from 17 others
What the payments were for
- Consulting fees$6,60053%
- Travel & lodging$8347%
- Food & beverage$4,97440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $8,984 |
| Alcon | 34 | $715 |
| Oyster Point Pharma, Inc. | 17 | $450 |
| Aerie Pharmaceuticals, Inc. | 14 | $353 |
| Novartis | 16 | $293 |
| Thea Pharma Inc. | 9 | $203 |
| Sun Pharmaceutical Industries Inc. | 8 | $182 |
| Bausch & Lomb Americas Inc. | 9 | $178 |
| Amgen(2 entities) | 8 | $166 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $154 |
| Tarsus Pharmaceuticals, Inc. | 6 | $145 |
| Harrow Eye, LLC | 4 | $123 |
| Sight Sciences, Inc. | 4 | $91 |
| Akorn Operating Company LLC | 4 | $83 |
| Ocular Therapeutix, Inc. | 3 | $55 |
| NEW World Medical,inc. | 3 | $49 |
| Topcon Healthcare, Inc. | 1 | $48 |
| Shire North American Group Inc | 2 | $39 |
| Glaukos Corporation | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $23 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,408 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 269 | $194,809 |
| LumiganBimatoprost | 304 | $192,316 |
| CombiganBrimonidine Tartrate/Timolol | 156 | $71,249 |
| RestasisCyclosporine | 50 | $62,713 |
| RhopressaNetarsudil Mesylate | 81 | $57,482 |
| Alphagan PBrimonidine Tartrate | 104 | $55,472 |
| XiidraLifitegrast | 46 | $53,159 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 87 | $37,309 |
| VyzultaLatanoprostene Bunod | 70 | $36,154 |
| Travatan ZTravoprost | 29 | $18,872 |
| Cosopt PfDorzolamide/Timolol/Pf | 34 | $17,899 |
| Latanoprost | 889 | $14,192 |
| AzoptBrinzolamide | 24 | $13,807 |
| ZioptanTafluprost/Pf | 20 | $13,071 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 55 | $10,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $8,984 | $381,749614 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $353 | $252,291350 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $178 | $89,312116 claims |
| AlconSimbrinza, Azopt | $715 | $51,116111 claims |
| NovartisTravatan Z | $293 | $18,87229 claims |
| Harrow Eye, LLCVevye | $123 | $8,41911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Libertyville
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.